Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab with GP induction chemoradiotherapy and maintenance in locally advanced nasopharyngeal carcinoma
ChiCTR2300078941Phase 2Recruiting
- Sponsor
- The Second People's Hospital of Neijiang
- Start
- Dec 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, gemcitabine and cisplatin in nasopharyngeal carcinoma (NPC), sponsored by The Second People's Hospital of Neijiang. Primary endpoint: Complete remission rate. Started Dec 2023; status: recruiting.
02
Drugs
tislelizumabgemcitabinecisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2300078941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078941.